The association between serum visfatin level and in-stent restenosis of drug-eluting stents

Li Bo; Fu Shiquan; Chen Qingmei; Liu Dandan; Huang Guangyin; Zhang Yu

doi:10.3969/j.issn.1674-4055.2018.01.18

Abstract：Objective To investigate the relationship between serum visfatin level and in-stent restenosis (ISR) after drug-eluting stents (DES) implantation. Methods From January 2015 to June 2017, a total of 420 patients with coronary heart disease who underwent DES implantation were included. According to the presence or absence of ISR, these patients were divided into the ISR (n=58) and non-ISR (n=362) groups. The clinical data between the 2 groups were compared, and ELISA method was used to measure the level of serum visfatin before and within 4h after procedure. Results The serum levels of visfatin before procedure were not different between ISR and non-ISR groups [(13.1±6.4) ng/ml vs. (12.5±5.9) ng/ml; P=0.48]. The serum visfatin level after procedure was (45.1 ±9.6) ng/ml and (34.7±7.5) ng/ml in ISR and non-ISR groups, respectively, with significant difference between the 2 groups (P<0.01). Result of multivariate logistic regression analysis indicated that post-procedural serum visfatin level (OR=1.84, 95%CI: 1.12~2.38; P<0.01), diabetes (OR=2.36, 95%CI: 1.16~4.80; P<0.05), stent length (OR=1.43, 95%CI: 1.05~1.96; P<0.05) and stent diameter (OR=0.62, 95%CI: 0.47~0.81; P<0.01) were independent predictors for ISR after drug-eluting stent implantation. Result of ROC curve analysis showed that the area under the curve for post-procedural visfatin to predict ISR was 0.82 (95%CI: 0.75~0.89), and the optimal cut-off value was 36.8 ng/ml, with a sensitivity of 74% and a specificity of 79%. Conclusion The serum visfatin level after placement of drug-eluting stents is closely associated with ISR, and it is an independent predictor for ISR.